MedTrace Logo

Clinical and Radiological Prognostic Factors of Acute Necrotizing Encephalopathy in Sohag University Hospital

NCT05853159 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2023-05-10

No results posted yet for this study

Summary

Acute necrotizing encephalopathy of childhood (ANEC) is a fulminant type of encephalopathy. Most reported cases occur in Asian children with the highest prevalence among patients between the age of 6 and 18 months. The most common clinical presentations are fever, rapid alteration in the level of consciousness, and seizures, in addition to characteristic findings in brain imaging that include, but are not limited to, bilateral thalamic lesions with supra and infra-tentorial lesions of variable dimensions.

The diagnosis of ANEC was determined by specific diagnostic criteria as described by Mizuguchi \[1\] which consist of

1. Encephalopathy preceded by viral febrile illness with rapid deterioration in the level of consciousness and convulsions.
2. Absent cerebrospinal fluid (CSF) pleocytosis.
3. Symmetric multifocal brain lesions.
4. Elevation in serum aminotransferase levels.
5. Exclusion of similar diseases. The ANE severity score was used to assess the severity of illness after admission for shock (3 points), brainstem lesions (2 points), age \>4 years (2 points), platelet (PLT) count \< 100,000 (1 point), and elevated CSF protein (1 point) was observed. \[3\] A total score of 9

Conditions

  • Acute Necrotizing Encephalopathy

Interventions

OTHER

Basic Laboratory investigations , Cerebrospinal fluid analysis

to detect severity and prognostic factors of Acute Necrotizing Encephalopathy

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
2 Months
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2024-05-01
Completion
2024-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05853159 on ClinicalTrials.gov